Transplant Trial Watch

To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.

The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].

The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.

Click on each trial for more detail of findings and quality.


March 2013

Kidney transplantation

Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
Billing H, Sander A, et al. Transplant International. 2013; 26(3): 331-338

Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): The phase III randomized MELT trial.
Bunnapradist S, Ciechanowski K, et al. American Journal of Transplantation. 2013; 13(3):760-769

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.
Carpenter M.A, Weir M.R, et al. Clinical Transplantation 2012; 26(4): E438-446.

Combination of epidural anaesthesia and general anaesthesia attenuates stress response to renal transplantation surgery.
Hadimioglu N, Ulugol H, et al. Transplantation Proceedings 2012; 44(10): 2949-54.

Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab F.S, Cibrik D, et al. Clinical Transplantation. 2013; 27(2): 217-226

Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R, Quaedackers M.E, et al. Transplantation. 94(5): 465-72, 2012.

Liver transplantation

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study.
Huang L, Li G. M, et al. Onco Targets and Therapy 2012; 5: 457-462.

Effect of low central venous pressure on postoperative pulmonary complications in patients undergoing liver transplantation.
Wang B, He H.K, et al. Surgery Today. 2013; 43(7): 777-781

Various organs

The effects of calcineurin inhibitors on prostanoid synthesis: a randomised cross-over study in healthy humans.
Ozbay L.A, Stubbe J, et al. Transplant International 2013; 26: 131-137.

Treatment of cytomegalovirus disease in solid organ transplant recipients: Markers of inflammation as predictors of outcome.
Rollag H, Asber A, et al. Transplantation 2012; 94 (10): 1060-1065.